Limited ERG11 Mutations Identified in Isolates of Candida auris Directly Contribute to Reduced Azole Susceptibility
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
Multiple Erg11 amino acid substitutions were identified in clinical isolates of Candida auris originating from India and Colombia. Elevated azole MICs were detected in Saccharomyces cerevisiae upon heterologous expression of C. auris ERG11 alleles that encoded for Y132F or K143R substitutions; however, expression of alleles encoding I466M, Y501H, or other clade-defined amino acid differences yielded susceptible MICs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Finally, in Candida auris, ERG11 polymorphisms as well as an increased number of ERG11 gene copies are thought to be responsible for its largely intrinsic azole resistance37–40”
From Drug resistance and tolerance in fungi. (2020) · cites this paper as [39]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Mutations in ERG11 also contribute to reduced azole susceptibility in the emerging fungal pathogen C. auris12–15, with a recent study highlighting a previously unreported substitution in Erg11 (F444L) identified in azole-resistant clade IV clinical isolates that has not been previously described in other reports15.”
From Molecular mechanisms governing antifungal drug resistance (2023) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“heterologous expression of C. auris ERG11 alleles carrying mutations encoding either the Y132F or K143R amino acid substitution on a low-copy-number episomal plasmid was observed to decrease fluconazole susceptibility in a haploid strain of Saccharomyces cerevisiae (13).”
From Mutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris (2020) · cites this paper as [13]
In the citing paper
“Heterologous expression of C. auris ERG11 alleles carrying the mutations leading to the Y132F and K143R substitutions on a low copy number episomal plasmid in Saccharomyces cerevisiae revealed that both mutations increase fluconazole resistance, but the specific contribution of these mutations to triazole resistance in C. auris has not been defined (14).”
From Delineation of the Direct Contribution of Candida auris ERG11 Mutations to Clinical Triazole Resistance (2021) · cites this paper as [14]
In the citing paper
“In C. auris, studies have suggested that point mutations in ERG11 contribute to azole resistance of clinical isolates (15).”
From Genetic Analysis of Candida auris Implicates Hsp90 in Morphogenesis and Azole Tolerance and Cdr1 in Azole Resistance (2019) · cites this paper as [15]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lockhart, S. R., Etienne, K. A., Vallabhaneni, S., Farooqi, J., Chowdhary, A., Govender, N. P., Colombo, A. L., Calvo, B., Cuomo, C. A., Desjardins, C. A., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw691 · Cited by 1,662 · cited 7×
“auris is divided into four major clades: South Asian, East Asian, South African, and South American (1).”
BackgroundSelf-citationMechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647 · cited 2×
“03 India (1) Y132F 64 to 128 ( 128) 4 to 16 (4) India (22) K143R 64 to 128 ( 128) 0.”
BackgroundSelf-citationChowdhary, A., Prakash, A., Sharma, C., Kordalewska, M., Kumar, A., Sarma, S., Tarai, B., Singh, A., Upadhyaya, G., Upadhyay, S., et al. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx480 · Cited by 577 · cited 3×
“Notably, a wild-type ERG11 genotype was reported in 4 of 5 isolates exhibiting low fluconazole MICs (1 to 2 g/ml) (6).”
BackgroundResultSelf-citationSanglard, D., Ischer, F., Koymans, L., & Bille, J. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.2.241 · Cited by 465
Muñoz, J. F., Gade, L., Chow, N. A., Loparev, V. N., Juieng, P., Berkow, E. L., Farrer, R. A., Litvintseva, A. P., & Cuomo, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-07779-6 · Cited by 458
Contribution of Clinically Derived Mutations in ERG11 to Azole Resistance in Candida albicans
Flowers, S. A., Colón, B., Whaley, S. G., Schuler, M. A., & Rogers, P. D. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.03470-14 · Cited by 294
Morio, F., Loge, C., Besse, B., Hennequin, C., & Le Pape, P. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2009.11.006 · Cited by 279
Genomic epidemiology of the UK outbreak of the emerging human fungal pathogen Candida auris
Rhodes, J., Abdolrasouli, A., Farrer, R. A., Cuomo, C. A., Aanensen, D. M., Armstrong-James, D., Fisher, M. C., & Schelenz, S. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0045-x · Cited by 246 · cited 3×
“auris-related infections in other parts of the world, such as the United States or United Kingdom, have been caused by strains that are genetically related to these clades (2, 3).”
BackgroundSagatova, A. A., Keniya, M. V., Wilson, R. K., Monk, B. C., & Tyndall, J. D. A. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00925-15 · Cited by 210
Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans
Xiang, M.-J., Liu, J.-Y., Ni, P.-H., Wang, S., Shi, C., Wei, B., Ni, Y.-X., & Ge, H.-L. (2013) · FEMS Yeast Research · doi:10.1111/1567-1364.12042 · Cited by 197
Research works printed but not linked: 1
- Clinical and Laboratory Standards Institute. 2017. Reference method for broth dilution antifungal susceptibility testing of yeasts—4th ed. CLSI document M27. Clinical and Laboratory Standards Institute, Wayne, PA.
Cited by
Antifungal Drug Resistance: Molecular Mechanisms in Candida albicans and Beyond
Lee, Y., Puumala, E., Robbins, N., & Cowen, L. E. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00199 · Cited by 801
Drug resistance and tolerance in fungi.
Berman, J., & Krysan, D. J. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0322-2 · Cited by 642
Muñoz, J. F., Gade, L., Chow, N. A., Loparev, V. N., Juieng, P., Berkow, E. L., Farrer, R. A., Litvintseva, A. P., & Cuomo, C. A. (2018) · Nature Communications · doi:10.1038/s41467-018-07779-6 · Cited by 458
Global epidemiology of emerging Candida auris
Rhodes, J., & Fisher, M. C. (2019) · Current Opinion in Microbiology · doi:10.1016/j.mib.2019.05.008 · Cited by 315
Molecular mechanisms governing antifungal drug resistance
Lee, Y., Robbins, N., & Cowen, L. E. (2023) · npj Antimicrobials and Resistance · doi:10.1038/s44259-023-00007-2 · Cited by 304
Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium
Arastehfar, A., Gabaldón, T., Garcia-Rubio, R., Jenks, J. D., Hoenigl, M., Salzer, H. J. F., Ilkit, M., Lass-Flörl, C., & Perlin, D. S. (2020) · Antibiotics · doi:10.3390/antibiotics9120877 · Cited by 292
Self-citationAhmad, S., & Alfouzan, W. (2021) · Microorganisms · doi:10.3390/microorganisms9040807 · Cited by 269
Review on Antifungal Resistance Mechanisms in the Emerging Pathogen Candida auris
Chaabane, F., Graf, A., Jequier, L., & Coste, A. T. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02788 · Cited by 223
Carolus, H., Pierson, S., Muñoz, J. F., Subotić, A., Cruz, R. B., Cuomo, C. A., & Van Dijck, P. (2021) · mBio · doi:10.1128/mbio.03333-20 · Cited by 211
“auris so far 201 (7-9, 14), and are situated in another ‘hotspot’ region of ERG11 (30, 31).”
BackgroundCandida auris—the growing menace to global health
Lone, S. A., & Ahmad, A. (2019) · Mycoses · doi:10.1111/myc.12904 · Cited by 208
Candida auris and multidrug resistance: Defining the new normal
Lockhart, S. R. (2019) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2019.103243 · Cited by 205
Mutations in TAC1B : a Novel Genetic Determinant of Clinical Fluconazole Resistance in Candida auris
Rybak, J. M., Muñoz, J. F., Barker, K. S., Parker, J. E., Esquivel, B. D., Berkow, E. L., Lockhart, S. R., Gade, L., Palmer, G. E., White, T. C., et al. (2020) · mBio · doi:10.1128/mbio.00365-20 · Cited by 202
Confirmation of fifth Candida auris clade by whole genome sequencing
Spruijtenburg, B., Badali, H., Abastabar, M., Mirhendi, H., Khodavaisy, S., Sharifisooraki, J., Taghizadeh Armaki, M., de Groot, T., & Meis, J. F. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2125349 · Cited by 164
“auris is associated with amino acid substitutions in ERG11 at position F126L, Y132F and K143R, while I466M and Y501H might contribute to reduced susceptibility [14].”
BackgroundCombined Antifungal Resistance and Biofilm Tolerance: the Global Threat of Candida auris
Kean, R., & Ramage, G. (2019) · mSphere · doi:10.1128/msphere.00458-19 · Cited by 152
“clade showed no effect on azole susceptibility (26).”
BackgroundA comprehensive overview of the medicinal chemistry of antifungal drugs: perspectives and promise
Howard, K. C., Dennis, E. K., Watt, D. S., & Garneau-Tsodikova, S. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00556k · Cited by 140
Abrogation of Triazole Resistance upon Deletion of CDR1 in a Clinical Isolate of Candida auris
Rybak, J. M., Doorley, L. A., Nishimoto, A. T., Barker, K. S., Palmer, G. E., & Rogers, P. D. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00057-19 · Cited by 141
“auris ERG11 alleles harboring mutations encoding the Y132F or K143R amino acid substitution were episomally expressed in Saccharomyces cerevisiae, fluconazole MICs were observed to increase (8).”
Kim, S. H., Iyer, K. R., Pardeshi, L., Muñoz, J. F., Robbins, N., Cuomo, C. A., Wong, K. H., & Cowen, L. E. (2019) · mBio · doi:10.1128/mbio.02529-18 · Cited by 136
“auris, studies have suggested that point mutations in ERG11 contribute to azole resistance of clinical isolates (15).”
BackgroundBranco, J., Miranda, I. M., & Rodrigues, A. G. (2023) · Journal of Fungi · doi:10.3390/jof9010080 · Cited by 164
Identification of Drug Resistant Candida auris
Kordalewska, M., & Perlin, D. S. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01918 · Cited by 124
Self-citationRybak, J. M., Barker, K. S., Muñoz, J. F., Parker, J. E., Ahmad, S., Mokaddas, E., Abdullah, A., Elhagracy, R. S., Kelly, S. L., Cuomo, C. A., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.11.024 · Cited by 120
Rybak, J. M., Cuomo, C. A., & David Rogers, P. (2022) · Current Opinion in Microbiology · doi:10.1016/j.mib.2022.102208 · Cited by 113
“cerevisiae, was not found to impact fluconazole or voriconazole MIC [22].”
BackgroundYadav, A., Singh, A., Wang, Y., Haren, M. H. V., Singh, A., de Groot, T., Meis, J. F., Xu, J., & Chowdhary, A. (2021) · Journal of Fungi · doi:10.3390/jof7020081 · Cited by 111
“The genomic investigation of drug resistant genes implicated in fluconazole resistance in the present study showed the presence of either K143R or Y132F mutations in ERG11 gene in clinical and environmental isolates of C. auris.”
BackgroundInfluentialSelf-citationMulti-omics Signature of Candida auris , an Emerging and Multidrug-Resistant Pathogen
Zamith-Miranda, D., Heyman, H. M., Cleare, L. G., Couvillion, S. P., Clair, G. C., Bredeweg, E. L., Gacser, A., Nimrichter, L., Nakayasu, E. S., & Nosanchuk, J. D. (2019) · mSystems · doi:10.1128/msystems.00257-19 · Cited by 99
Candida auris : multi-omics signature of an emerging and multidrug-resistant pathogen
Zamith-Miranda, D., Heyman, H. M., Cleare, L. G., Couvillion, S., Clair, G., Bredeweg, E., Gacser, A., Nimrichter, L., Nakayasu, E. S., & Nosanchuk, J. D. (2019) · doi:10.1101/528232 · Cited by 99
Nine Things Genomics Can Tell Us About Candida auris
Chybowska, A. D., Childers, D. S., & Farrer, R. A. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.00351 · Cited by 96
Kim, H. Y., Nguyen, T. A., Kidd, S. E., Chambers, J., Alastruey‐Izquierdo, A., Shin, J.-H., Dao, A., Forastiero, A., Wahyuningsih, R., Chakrabarti, A., et al. (2024) · Medical Mycology · doi:10.1093/mmy/myae042 · Cited by 123
“28 , 85 The wide MICs distributions to other azoles suggest variable acquired resistance.”
BackgroundKeighley, C., Garnham, K., Harch, S. A. J., Robertson, M., Chaw, K., Teng, J. C., & Chen, S. C.-A. (2021) · Current Fungal Infection Reports · doi:10.1007/s12281-021-00420-y · Cited by 87
Bing, J., Hu, T., Zheng, Q., Muñoz, J. F., Cuomo, C. A., & Huang, G. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01466-20 · Cited by 86
What do we know about the biology of the emerging fungal pathogen of humans Candida auris?
Bravo Ruiz, G., & Lorenz, A. (2021) · Microbiological Research · doi:10.1016/j.micres.2020.126621 · Cited by 85
Drug Resistance and Novel Therapeutic Approaches in Invasive Candidiasis
Murphy, S. E., & Bicanic, T. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.759408 · Cited by 83
Novel ERG11 and TAC1b Mutations Associated with Azole Resistance in Candida auris
Li, J., Coste, A. T., Liechti, M., Bachmann, D., Sanglard, D., & Lamoth, F. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02663-20 · Cited by 82
“auris azole-resistant isolates, some of them being associated with specific geographic clades (5, 16).”
BackgroundSingh, A. K., Singh, P. K., de Groot, T., Kumar, A., Mathur, P., Tarai, B., Sachdeva, N., Upadhyaya, G., Sarma, S., Meis, J. F. G. M., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz029 · Cited by 87
Self-citationAhmad, S., Khan, Z., Al‐Sweih, N., Alfouzan, W., & Joseph, L. (2020) · Mycoses · doi:10.1111/myc.13022 · Cited by 79
Strategies to Prevent Transmission of Candida auris in Healthcare Settings
Ahmad, S., & Asadzadeh, M. (2023) · Current Fungal Infection Reports · doi:10.1007/s12281-023-00451-7 · Cited by 77
In Vitro Antifungal Resistance of Candida auris Isolates from Bloodstream Infections, South Africa
Maphanga, T. G., Naicker, S. D., Kwenda, S., Muñoz, J. F., van Schalkwyk, E., Wadula, J., Nana, T., Ismail, A., Coetzee, J., Govind, C., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00517-21 · Cited by 78
“contrast, a very low prevalence of fluconazole resistance has been reported for clade IV Colombian isolates and clade II Japanese isolates (2, 22, 23).”
BackgroundRosam, K., Monk, B. C., & Lackner, M. (2020) · Journal of Fungi · doi:10.3390/jof7010001 · Cited by 95
“Genus Species Phylum AA Change in Active Site 2nd Mutation Gene Correlated Resistance * Ref. an im al -p at ho ge ni c fu ng i Ajellomyces capsulatus Ascomycota Y136F ERG11 FLC, ITC [28] Aspergillus fumigatus Ascomycota Y121F (TR46) T289A cyp51A VCZ [31–35] Aspergillus fumigatus Ascomycota I301 cyp51A FLC [36] Aspergi…”
BackgroundInfluentialCandida auris: A Quick Review on Identification, Current Treatments, and Challenges
Černáková, L., Roudbary, M., Brás, S., Tafaj, S., & Rodrigues, C. F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094470 · Cited by 91
“auris ERG11 mutations resulted directly in reduced azole susceptibility [90].”
BackgroundMolecular Epidemiology of Candida Auris Outbreak in a Major Secondary-Care Hospital in Kuwait
Alfouzan, W., Ahmad, S., Dhar, R., Asadzadeh, M., Almerdasi, N., Abdo, N. M., Joseph, L., de Groot, T., Alali, W. Q., Khan, Z., et al. (2020) · Journal of Fungi · doi:10.3390/jof6040307 · Cited by 74
“[60] also reported that clade I and clade IV isolates with Y132F mutation exhibit cross-resistance to voriconazole while isolates with K143R mutation remain susceptible to voriconazole.”
BackgroundBall, B., Langille, M. G. I., & Geddes‐McAlister, J. (2020) · mBio · doi:10.1128/mbio.01020-20 · Cited by 84
“offers value as potential resistant molecular markers for clade specific isolates (39).”
BackgroundIyer, K. R., Camara, K., Daniel-Ivad, M., Trilles, R., Pimentel-Elardo, S. M., Fossen, J. L., Marchillo, K., Liu, Z., Singh, S., Muñoz, J. F., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20183-3 · Cited by 72
Rybak, J. M., Sharma, C., Doorley, L. A., Barker, K. S., Palmer, G. E., & Rogers, P. D. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.01585-21 · Cited by 69
Update on the Pathogenesis, Virulence, and Treatment of Candida auris
Watkins, R. R., Gowen, R., Lionakis, M., & Ghannoum, M. (2022) · Pathogens and Immunity · doi:10.20411/pai.v7i2.535 · Cited by 68
“auris strains when compared to a Saccharomyces cerevisiae control [68].”
ResultHou, X., Lee, A., Jiménez-Ortigosa, C., Kordalewska, M., Perlin, D. S., & Zhao, Y. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01811-18 · Cited by 66
“auris ERG11 alleles in Saccharomyces cerevisiae (10).”
BackgroundSelf-citationMultidrug-resistant Candida auris : an epidemiological review
Chakrabarti, A., & Singh, S. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1750368 · Cited by 66
“A recent study on the phylogenetic analysis of 304 isolates reported widespread dissemination of Clade I in countries like Canada, France, Germany, India, Kenya, Pakistan, Saudi Arabia, United Kingdom, United Arab Emirates, and United States; Clade II in Canada, Japan, South Korea, and United States; Clade III in Aust…”
BackgroundInfluentialHu, S., Zhu, F., Jiang, W., Wang, Y., Quan, Y., Zhang, G., Gu, F., & Yang, Y. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.658329 · Cited by 64
“Drug Resistance Loci Among the isolates reported to date, the major drug resistance loci for azoles are ERG11, CDR1, and MDR1 (Healey et al., 2018; Kordalewska et al., 2018; Rybak et al., 2019); the major drug resistance loci for AMB are ERG 2, 3, 5, 6, or 11 (Rhodes et al.”
BackgroundIdentification of Mycoses in Developing Countries
Arastehfar, A., Wickes, B. L., Ilkit, M., Pincus, D. H., Daneshnia, F., Pan, W., Fang, W., & Boekhout, T. (2019) · Journal of Fungi · doi:10.3390/jof5040090 · Cited by 63
Fluconazole-resistant Candida parapsilosis: A new emerging threat in the fungi arena
Escribano, P., & Guinea, J. (2022) · Frontiers in Fungal Biology · doi:10.3389/ffunb.2022.1010782 · Cited by 74
Gómez-Gaviria, M., Martínez-Álvarez, J. A., Chávez-Santiago, J. O., & Mora-Montes, H. M. (2023) · Infection and Drug Resistance · doi:10.2147/idr.s402754 · Cited by 69
Deciphering the Mrr1/Mdr1 Pathway in Azole Resistance of Candida auris
Li, J., Coste, A. T., Bachmann, D., Sanglard, D., & Lamoth, F. (2022) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00067-22 · Cited by 59
Corzo-León, D., Peacock, M., Rodríguez‐Zulueta, P., Salazar-Tamayo, G., & MacCallum, D. M. (2020) · Medical Mycology · doi:10.1093/mmy/myaa098 · Cited by 64
“APACHE II score (median, IQR) 21 (17-27) 23 (15-29)+ 13 (5-21)++”
BackgroundSharma, C., & Kadosh, D. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011190 · Cited by 63
“It is pertinent to mention here that C. auris in vitro evolution experiments have used MIC measurements to define antifungal resistance.”
BackgroundInfluentialAsadzadeh, M., Mokaddas, E., Ahmad, S., Abdullah, A. A., de Groot, T., Meis, J. F., & Shetty, S. A. (2022) · Mycoses · doi:10.1111/myc.13419 · Cited by 55
Mayr, E.-M., Ramírez-Zavala, B., Krüger, I., & Morschhäuser, J. (2020) · mSphere · doi:10.1128/msphere.00279-20 · Cited by 55
The effect of antifungal resistance development on the virulence of Candida species
Bohner, F., Papp, C., & Gácser, A. (2022) · FEMS Yeast Research · doi:10.1093/femsyr/foac019 · Cited by 78
“…linked to azole resistance in Candida species, as following to the inhibition of ERG11 by azoles, this enzyme is responsible for the synthesis of the toxic sterol product, which leads to changes of membrane permeability (Cowen and Steinbach 2008, Robbins et al. 2016, 2017, Healey et al. 2018) (Fig.”
Antifungal drug resistance in Candida: a special emphasis on amphotericin B
Ahmady, L., Gothwal, M., Mukkoli, M. M., & Bari, V. K. (2024) · Apmis · doi:10.1111/apm.13389 · Cited by 65
Azole resistance in Candida auris: mechanisms and combinatorial therapy
Jangir, P., Kalra, S., Tanwar, S., & Bari, V. K. (2023) · Apmis · doi:10.1111/apm.13336 · Cited by 61
“lyzes C-14 demethylation of lanosterol to form 4,400-dimethyl cholesta-8,14,24-triene-3-beta-ol in ergosterol biosynthesis pathway [55].”
BackgroundArıkan-Akdağlı, S., Ghannoum, M. A., & Meis, J. F. G. M. (2018) · Journal of Fungi · doi:10.3390/jof4040129 · Cited by 54
Prevalence and Therapeutic Challenges of Fungal Drug Resistance: Role for Plants in Drug Discovery
Marquez, L., & Quave, C. L. (2020) · Antibiotics · doi:10.3390/antibiotics9040150 · Cited by 63
Arendrup, M. C., Chowdhary, A., Jørgensen, K. M., & Meletiadis, J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00656-20 · Cited by 49
“position 132), K143R, and F126T alterations in the Erg11 target protein (7, 13), but involvement of efflux pumps and target gene upregulation have subsequently been demonstrated in aging cells (14).”
BackgroundSelf-citationEmerging Issues in Antifungal Resistance
Perfect, J. R., & Ghannoum, M. (2020) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2020.05.003 · Cited by 47
Emerging and future strategies in the management of recalcitrant Candida auris
Bandara, N., & Samaranayake, L. P. (2022) · Medical Mycology · doi:10.1093/mmy/myac008 · Cited by 50
Ceballos-Garzón, A., Peñuela, A., Valderrama, S., Vargas‐Casanova, Y., Ariza, B., & Parra‐Giraldo, C. M. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1136217 · Cited by 49
“Among the nonsense mutations (C. albicans 6; C. auris 5; and C. parapsilosis 2), three amino acid substitutions related with FLC-resistance (T220L, Y132F, K143R) were found from which Y132F was the most detected.”
BackgroundInfluentialCastanheira, M., Deshpande, L. M., Rhomberg, P. R., & Carvalhaes, C. G. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00570-24 · Cited by 44
“We observed the Erg11 alterations Y132F and/or K143R in isolates from Clades I and IV and the F126L alteration in isolates from Clade III; these alterations are known to confer fluconazole resistance and only occur in these specific Clades (2, 18).”
BackgroundApplication of Machine Learning Classifier to Candida auris Drug Resistance Analysis
Li, D., Wang, Y., Hu, W., Chen, F., Zhao, J., Chen, X., & Li, H. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.742062 · Cited by 40
“Also, it has been reported that these mutations are associated with geographic cues, with mutations leading to Y132F and K143R associated with isolates belonging to South Asian and South American groups (Healey et al., 2018).”
BackgroundPfaller, M. A., Messer, S. A., Deshpande, L. M., Rhomberg, P. R., Utt, E. A., & Castanheira, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02031-20 · Cited by 37
“auris demonstrates that, as with Candida albicans, resistance to fluconazole and other azoles is mediated by mutations in the gene ERG11 and potentially augmented by the overexpression of CDR1 efflux pumps (19, 20).”
BackgroundResultInfluentialOverview about Candida auris: What's up 12 years after its first description?
Désoubeaux, G., Coste, A. T., Imbert, C., & Hennequin, C. (2022) · Journal de Mycologie Médicale · doi:10.1016/j.mycmed.2022.101248 · Cited by 43
de Oliveira, J. S., Pereira, V. S., Castelo‐Branco, D. D. S. C. M., Cordeiro, R. D. A., Sidrim, J. J. C., Brilhante, R. S. N., & Rocha, M. F. G. (2020) · Canadian Journal of Microbiology · doi:10.1139/cjm-2019-0531 · Cited by 39
Candida auris Urinary Tract Infections and Possible Treatment
Griffith, N. C., & Danziger, L. H. (2020) · Antibiotics · doi:10.3390/antibiotics9120898 · Cited by 48
“Fluconazole resistance mechanisms are not completely understood, but are known to include EGR11 mutations and duplications, as well as efflux pumps [18,19].”
BackgroundAlJindan, R. Y., AlEraky, D. M., Mahmoud, N., Abdalhamid, B. A., Almustafa, M., AbdulAzeez, S., & Borgio, J. F. (2020) · Journal of Fungi · doi:10.3390/jof7010018 · Cited by 39
“These findings concur with a study in 2018, which concluded that F132Y and K143R mutations could be initial markers for azole resistance in South Asian and South American clade [33].”
ResultKekana, D., Naicker, S. D., Shuping, L., Velaphi, S., Nakwa, F. L., Wadula, J., Govender, N. P., & GERMS-SA1, F. (2023) · Emerging infectious diseases · doi:10.3201/eid2910.230181 · Cited by 42
“We extract - ed 2 genes from each resistant C. auris genome and assessed for any point mutations (i.e., substitutions, duplications): ERG11 , which is transcribed into an azole target; and FKS1 , an echinocandin target gene ( 27 ).”
BackgroundPlant-Derived Substances in the Fight Against Infections Caused by Candida Species
Guevara-Lora, I., Braś, G., Karkowska‐Kuleta, J., Gonzalez‐Gonzalez, M., Ceballos, K., Sidlo, W., & Rąpała‐Kozik, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176131 · Cited by 43
“tropicalis is currently observed [54,70] as a consequence of the massive preventive application of fluconazole [71,72] and common use of agricultural fungicides, structurally similar to azoles [73].”
BackgroundSingh, S., Barbarino, A. M., Youssef, E. G., Coleman, D., Gebremariam, T., & Ibrahim, A. S. (2023) · Journal of Fungi · doi:10.3390/jof9010103 · Cited by 34
“) across all clades, thus making it difficult to develop new drug variants within the existing antifungal class (azoles, polyenes, and echinocandins) [1,24,25].”
BackgroundTan, Y. E., Teo, J. Q.-M., Rahman, N. B. A., Ng, O. T., Marimuthu, K., Tan, A. L., Koh, T. H., & Ong, R. T. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.09.016 · Cited by 37
Derkacz, D., Bernat, P., & Krasowska, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031631 · Cited by 33
Molecular Diagnostics in the Times of Surveillance for Candida auris
Kordalewska, M., & Perlin, D. S. (2019) · Journal of Fungi · doi:10.3390/jof5030077 · Cited by 38
“FKS1 S639P [54] or S639F [9,17] and ERG11 F126L, Y132F, or K143R [16,55,56] are the only mutations clearly linked to the clinical failure due to azole and echinocandin resistance, respectively.”
BackgroundSelf-citationWilliamson, B., Wilk, A. S., Guerrero, K. D., Mikulski, T. D., Elias, T. N., Sawh, I., Cancino-Prado, G., Gardam, D., Heath, C. H., Govender, N. P., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01624-21 · Cited by 30
“Fluconazole and voriconazole MICs of the first six strains were previously reported (15); however, these MICs were repeated in tandem with the newly engineered strains and are presented here for comparison.”
BackgroundMethodSelf-citationCheng, Y., Roma, J. S., Shen, M., Fernandes, C. M., Tsang, P. S., Forbes, H. J., Boshoff, H. I., Lazzarini, C., Poeta, M. D., Zheng, W., et al. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01305-20 · Cited by 30
“Gene mutations in the ERG11 gene encoding the target of azole antifungal drugs (cytochrome P450 lanosterol 14a-demethylase) are found in the South American (Y132F) and South Asian (Y132F or K143R) clades and are associated with reduced susceptibility to fluconazole (6, 11).”
BackgroundPathogenesis, Prophylaxis, and Treatment of Candida auris
Preda, M., Chivu, R. D., Diţu, L.-M., Popescu, O., & Manolescu, L. S. C. (2024) · Biomedicines · doi:10.3390/biomedicines12030561 · Cited by 38
“In actuality, longer exposure times combined with larger doses of this disinfectant were necessary to reduce regrowth; yet, even then, the pathogen could not be eliminated [54].”
InfluentialWang, Y., & Xu, J. (2024) · Journal of Fungi · doi:10.3390/jof10010086 · Cited by 31
“This mutation has been frequently reported for FLU-resistant C. auris strains [13,41,42].”
BackgroundA decade after the emergence of Candida auris: what do we know?
ElBaradei, A. (2020) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-020-03886-9 · Cited by 30
“and colleagues demonstrated that the Y132F mutation significantly reduced susceptibility to azoles [56].”
BackgroundGarcía‐Effrón, G. (2021) · Journal of Fungi · doi:10.3390/jof7030197 · Cited by 31
Silva, L. N., de Mello, T. P., Ramos, L. S., Branquinha, M. H., & dos Santos, A. L. S. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191025152412 · Cited by 29
Emergence and Genomic Characterization of Multidrug Resistant Candida auris in Nigeria, West Africa
Oladele, R. O., Uwanibe, J. N., Olawoye, I. B., Ettu, A.-W. O.-O., Meis, J. F. G. M., & Happi, C. T. (2022) · Journal of Fungi · doi:10.3390/jof8080787 · Cited by 36
Genomic Characterizations of Clade III Lineage of Candida auris , California, USA
Price, T. K., Mirasol, R., Ward, K. W., Dayo, A. J., Hilt, E. E., Chandrasekaran, S., Garner, O. B., Maurice, A. D. S., & Yang, S. (2021) · Emerging infectious diseases · doi:10.3201/eid2704.204361 · Cited by 26
“auris (7) and are a common feature of clade III isolates (12).”
BackgroundCell Wall-Modifying Antifungal Drugs
Perlin, D. S. (2019) · Current topics in microbiology and immunology · doi:10.1007/82_2019_188 · Cited by 30
Self-citationInsights into the Multi-Azole Resistance Profile in Candida haemulonii Species Complex
Silva, L. N., Ramos, L. S., de Oliveira, S. S. C., Magalhães, L. B., Squizani, E. D., Kmetzsch, L., Vainstein, M. H., Branquinha, M. H., & dos Santos, A. L. S. (2020) · Journal of Fungi · doi:10.3390/jof6040215 · Cited by 27
“cerevisiae [45,46], were not identified in our isolates.”
BackgroundBiswas, C., Wang, Q., van Hal, S. J., Eyre, D. W., Hudson, B. J., Halliday, C. L., Mazsewska, K., Gordon, A. K., Lee, A. S., Irinyi, L., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa158 · Cited by 29
“(ERG11, MDR1, CDR1 [azole resistance], FKS1 [echinocandin resistance], and ERG2, ERG3, ERG5, ERG6 [amphotericin B resistance]) [19, 20] were examined for SNPs using the criteria above (CLC Genomics Workbench; Bio, version 7.”
Dekkerová, J., Černáková, L., Kendra, S., Borghi, E., Ottaviano, E., Willinger, B., & Bujdáková, H. (2022) · Journal of Fungi · doi:10.3390/jof8080783 · Cited by 23
Ashkenazi‐Hoffnung, L., & Danziger, C. R. (2023) · Journal of Fungi · doi:10.3390/jof9020176 · Cited by 29
Candida auris: The Canary in the Mine of Antifungal Drug Resistance
Montoya, M. C., Moye-Rowley, W. S., & Krysan, D. J. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00239 · Cited by 21
Identification and Elimination of Antifungal Tolerance in Candida auris
Rasouli Koohi, S., Shankarnarayan, S. A., Galon, C. M., & Charlebois, D. A. (2023) · Biomedicines · doi:10.3390/biomedicines11030898 · Cited by 20
Williams, C. C., Gregory, J., & Usher, J. (2024) · Microbiology · doi:10.1099/mic.0.001512 · Cited by 26
“Three hot spot regions exist within ERG11 , aas 105–165, 266–287 and 405–488, and these have been supported by various studies identifying SNPs within these regions leading to increased MICs against azoles [29, 68].”
BackgroundDrug repurposing against Candida auris: A systematic review
Izadi, A., Gharehbolagh, S. A., Sadeghi, F., Talebi, M., Darmiani, K., Zarrinnia, A., Zarei, F., Peymaeei, F., Khojasteh, S., Borman, A. M., et al. (2022) · Mycoses · doi:10.1111/myc.13477 · Cited by 23
Candida auris in Austria—What Is New and What Is Different
Spettel, K., Kriz, R., Wu, C. C., Achter, L., Schmid, S., Galazka, S., Selitsch, B., Camp, I., Makristathis, A., Lagler, H., et al. (2023) · Journal of Fungi · doi:10.3390/jof9020129 · Cited by 21
Toepfer, S., Lackner, M., Keniya, M. V., & Monk, B. C. (2023) · Journal of Fungi · doi:10.3390/jof9020168 · Cited by 20
Detection of Candida auris Antifungal Drug Resistance Markers Directly from Clinical Skin Swabs
Kordalewska, M., Lee, A., Zhao, Y., & Perlin, D. S. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01754-19 · Cited by 20
“Moreover, sequencing of amplified FKS1 and ERG11 genes (6, 10) revealed that all recovered isolates presented WT FKS1 and ERG11 genotypes (Table 1).”
BackgroundSelf-citationBergin, S. A., Doorley, L. A., Rybak, J. M., Wolfe, K. H., Butler, G., Cuomo, C. A., & Rogers, P. D. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01619-23 · Cited by 24
Ettadili, H., & Vural, C. (2024) · Brazilian Journal of Microbiology · doi:10.1007/s42770-023-01239-0 · Cited by 20
“Indeed, fluconazole resistance in C. auris was associated with different mutations in the ERG11 gene known as amino acid substitutions at some specific positions (e.g., F126T or F126L or V125A in South Africa, Y132F or K143R in India, Y132F in Venezuela) [11, 51, 53, 54].”
Candida auris: A focused review for emergency clinicians
Long, B., Lacy, A. J., Koyfman, A., & Liang, S. Y. (2024) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2024.07.062 · Cited by 18
Rodrigues, L. S., Gazara, R. K., Passarelli‐Araujo, H., Valengo, A. E., Pontes, P. V. M., da Fonseca, R. N., de Souza, R. F., Venâncio, T. M., & Dalla-Costa, L. M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01535 · Cited by 17
Metadata
- Authors
- Healey, K. R., Kordalewska, M., Jiménez Ortigosa, C., Singh, A., Berrío, I., Chowdhary, A., & Perlin, D. S.
- Affiliations
- Rutgers Health (US)
- Public Health Research Institute, New Jersey Medical School, Rutgers Biomedical and Health Sciences, Newark, New Jersey, USA
- University of Delhi (IN)
- Municipality of Medellín (CO)
- Corresponding author
- Healey, Kelley R.
- Perlin, David S.
- ORCID
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2018-10
- Volume
- 62
- Issue
- 10
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC6153782
- OpenAlex
- W2886356978
- Cited by
- 165
- References
- 21
- Citations by year
- 2026: 14 · 2025: 9 · 2024: 22 · 2023: 24 · 2022: 18 · 2021: 24 · 2020: 30 · 2019: 21 · 2018: 3
- FWCI
- 14.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Greater South Information System
- Funders
- HHS | Centers for Disease Control and Prevention (BAA FY2017-OADS-01)
- Arnold and Mabel Beckman Foundation
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Fungal and yeast genetics research
- Keywords
- Candida auris, ERG11, azole resistance, azole susceptibility, amino acid substitutions, minimum inhibitory concentration, heterologous expression, clinical isolates
- MeSH terms
- Antifungal Agents, Azoles, Candida, Cytochrome P-450 Enzyme System, Microbial Sensitivity Tests, Mutation, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.